Intuitive Surgical Stock Performance
Intuitive Surgical shares closed at $377.16, declining 0.85% in the most recent session, per SID market data. The stock has experienced notable weakness across multiple timeframes, falling 4.4% over the past month and 9.46% over the trailing three months. Over the past year, ISRG has declined approximately 31.09%, reflecting broader pressure on high-multiple healthcare growth names. The stock currently trades just above its 50-day moving average of $375.38 but remains significantly below its 200-day moving average of $445.59, indicating a sustained downtrend according to Massive/Polygon technical data. The 14-day RSI reads 53.5, placing the stock in neutral momentum territory, neither overbought nor oversold. ISRG carries a beta of 1.686, indicating substantially higher volatility than the broader market. Average daily trading volume stands at approximately 2.26 million shares, supporting adequate liquidity for institutional positioning.
Intuitive Surgical Valuation Analysis
Intuitive Surgical commands a market capitalization of approximately $195.5 billion, making it one of the most valuable companies in the healthcare sector, per SID market data. The stock trades at a price-to-earnings ratio of 71.05, reflecting a substantial premium to both the broader market and the healthcare sector median. The PEG ratio stands at 13.30, according to SEC filings and derived valuation models, suggesting the current earnings multiple significantly exceeds the company's projected growth rate. ISRG's price-to-book ratio of 11.53 further underscores the premium investors assign to the company's dominant position in robotic-assisted surgery. The company pays no dividend, consistent with its growth-oriented capital allocation strategy. Despite the year-long price decline of over 31%, the valuation remains elevated by conventional metrics, reflecting the market's long-term confidence in the da Vinci surgical platform's expanding global adoption and recurring revenue model.
Smart Money Activity for ISRG
Intuitive Surgical's composite smart money score stands at 42 out of 100, registering a neutral signal, per SID market data. The institutional component scores a perfect 25 out of 25, reflecting robust and sustained institutional ownership among major fund managers according to 13F institutional filings. However, the insider trading component scores 0 out of 25, the lowest possible reading. SEC Form 4 filings reveal five insider transactions over the past 90 days, consisting of just one purchase against four sales, indicating a clear pattern of net insider disposition. Dark pool activity registers at 5 out of 25, suggesting limited off-exchange accumulation by large block traders. Congressional trading activity scores 12 out of 25, indicating moderate engagement by lawmakers in ISRG shares. The divergence between strong institutional conviction and weak insider sentiment creates a mixed signal for investors evaluating directional positioning. The overall neutral composite score reflects these offsetting dynamics across the four smart money categories.
Intuitive Surgical Earnings Outlook
Intuitive Surgical has delivered a consistent pattern of upside earnings surprises across its three most recently reported quarters, according to company earnings reports. In the most recent reported quarter, ISRG posted earnings per share of $2.80 against a consensus estimate of $2.41, representing a positive surprise of $0.39. The prior quarter showed even stronger outperformance, with actual EPS of $2.50 versus estimates of $1.92, a beat of $0.58 per share. The quarter before that delivered $2.53 in EPS against expectations of $2.09, a $0.44 upside surprise. Looking ahead, analyst estimates project EPS of $2.41 for the upcoming quarter with results expected on July 21, 2026. The three consecutive double-digit percentage beats suggest systematic analyst underestimation of the company's earnings power, driven by procedure volume growth and system placements that have repeatedly exceeded forecasted levels.
Wall Street Analyst Ratings for ISRG
Wall Street analyst sentiment on Intuitive Surgical remains generally constructive but reflects some recent divergence, per SID consensus data. In the most recent action on September 8, 2026, BTIG reiterated its Buy rating on the stock. Oppenheimer upgraded ISRG to Outperform from Perform on August 12, signaling renewed confidence in the company's growth trajectory. However, HSBC moved in the opposite direction on July 30, downgrading shares to Hold from Buy, according to Wall Street analyst reports. Mizuho maintained its Neutral stance on July 17, while TD Cowen reiterated its Buy rating on the same date, reflecting the split in analyst conviction. The mix of ratings highlights a debate centered on valuation concerns versus the company's operational momentum and consistent earnings beats. With the stock's P/E ratio exceeding 71, some analysts appear cautious about the current risk-reward profile despite acknowledging Intuitive Surgical's dominant competitive position in robotic surgery.
